Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1995-05-30
1996-07-02
Robinson, Douglas W.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
53612312, 5361231, 536124, A61K 31715
Patent
active
055322239
ABSTRACT:
The present invention relates to neutral soluble .beta.-glucans which exert potent and specific hematopoietic and immunological effects without stimulating the production of certain cytokines, to preparations containing the novel .beta.-glucans, and to a novel manufacturing process therefor. The neutral soluble glucan preparation has a high affinity for the .beta.-glucan receptor of human monocytes and retains two primary biological (or immunological) activities, (1) the enhancement of microbicidal activity of phagocytic cells, and (2) monocyte and neutrophil hemopoietic activity. Unlike soluble glucans described in the prior art, the neutral soluble glucan of this invention neither induces nor primes IL-1 and TNF production in vitro and in vivo. Safe and efficacious preparations of neutral soluble glucan of the present invention can be used in therapeutic and/or prophylactic treatment regimens of humans and animals to enhance their immune response, without stimulating the production of certain biochemical mediators (e.g., IL-1, TNF and leukotrienes) that can cause detrimental side effects, such as fever and inflammation.
REFERENCES:
patent: 4138479 (1979-02-01), Truscheit et al.
patent: 4237266 (1980-12-01), Sugiura et al.
patent: 4707471 (1987-11-01), Larm et al.
patent: 4739046 (1988-04-01), DiLuzio et al.
patent: 4761402 (1988-08-01), Williams et al.
patent: 4810646 (1989-03-01), Jamas et al.
patent: 5057503 (1991-10-01), Czop et al.
patent: 5234908 (1993-08-01), Szabo et al.
patent: 5322841 (1994-06-01), Jamas et al.
Tumori, vol. 74, issued 1988, Lerza et al, "Studies on Hemotoxicity of Cyclophosphamide, Doxorubicin and Cis-Diamminodichloroplatinum Combined with Sodium-2-Mercaptoethane Sulfonate", see pp. 333-337.
Cancer Research, vol. 52, issued 01 Aug. 1992, Damia et al, "Prevention of Acute Chemotherapy-Induced Death in Mice by Recombinant Human Interleukin 1: Protection from Hematological and Nonhematological Toxicities", see pp. 4082-4089.
Cancer Research, vol. 44, issued Sep. 1984, Evans et al, "Modification of the Bone Marrow Toxicity of Cis-Diamminedichloroplatinum(II) in Mice by Diethyldithiocarbamate", see pp. 3686-3690.
Cancer Research, vol. 54, issued 01 Feb. 1994, Green et al, "Preclinical Evaluation of WR-151327: An Orally Active Chemotherapy Protector", see pp. 738-741.
Cancer Letters, vol. 79, issued 1994, Yoshizawa et al, "Effects of Natural Human Interleukin-6 on Thrombopoiesis and Tumor Progression in Tumor-Bearing Mice", pp. 83-89.
Biotherapy, vol. 7, issued 1994, Patchen et al, "Mast Cell Growth Factor (C-kit Ligand) in Combination with Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin-3: in vivo Hemopoietic effects in Irradiated Ice compared to in vivo effects", see pp. 13-26.
Experimental Hematology, vol. 21, issued 1993, Patchen et al, "Effects of Combined Administration of Interleukin-6 and Granulocyte Colony-Stimulating Factor on Recovery from Radiation-Induced Hemopoietic Aplasia", see pp. 338-344.
Seminars in Oncology, vol. 21, No. 5, issued Oct. 1994, "Granulocyte Colony-Stimulating Factor and Amifostine (Ethyol) Synergize to Enhance Hemopoietic Reconstitution and Increase Survival in Irradiated Animals" see pp. 26-32.
Janusz, M. J., et al., "Isolation of Soluble Yeast .beta.-Glucan that Inhibit Human Monocyte Phagocytosis Mediated by .beta.-Glucan Receptors," J. Immunol., 137:3270-3276 (1986).
Manners, D. J., et al., "The Structure of a .beta.-(1.fwdarw.3)-D-Glucan from Yeast Cell Walls," Biochem. J., 135:19-30 (1973).
Williams, D. L., et al., "Pre-clinical Safety Evaluation of Soluble Glucan," Chemical Abstracts, 109:66566q (1988).
Fleet, G. H., et al., "Isolation and Composition of an Alkali-Soluble Glucan from the Cell Walls of Saccharomyces cerevisiae," Chemical Abstracts, 85:89819z (1976).
Bacon, J., et al., "The Glucan Components of the Cell Wall of Baker's Yeast (Saccharomyces cerevisiae) Considered in Relation to its Ultrastructure," Biochem. J., 114:557-567 (1969).
Vestnik Federalniho Uradu Pro Vynalezy, 10:111 (1989).
Vestnik Federalniho Uradu Pro Vynalezy, 11:122-123 (1989).
Onderdonk, A. B., et al., "Anti-Infective Effect of Poly-.beta.1-6-Glucotrisyl-.beta.1-3-Glucopyranose Glucan In Vivo," Infec. Immun., 60:1642-1647 (1992).
Abel, G. and Czop, J. K., "Activation of Human Monocyte GM-CSF and TNF-.alpha. Production by Particulate Yeast Glucan," International Congress for Infectious Diseases, Montreal, Canada (Abstract), (1990).
Chihara, G., et al., "Lentinan as a Host Defense Potentiator (HPD)," Int. J. Immunotherapy, V(4):145-154 (1989).
Sherwood, E. R., et al., "Enhancement of Interleukin-1 and Interleukin-2 Production by Soluble Glucan," Int. J. Immunopharmac., 9(3):261-267 (1987).
Williams, D. L., et al., "Pre-clinical Safety Evaluation of Soluble Glucan," Int. J. Immunopharmac., 10(4):405-414 (1988).
Browder, W., et al., "Beneficial Effect of Enhanced Macrophage Function in the Trauma Patient," Ann. Surg., 605-613 (1990).
Fleet, G. H., et al., "Isolation and Composition of an Alkali-soluble Glucan from the Cell Walls of Saccharomyces cerevisiae," Journal of General Microbiology, 94:180-192 (1976).
Miyazaki, T., et al., "Structural Examination of Antitumour, Water-Soluble Glucans from Grifora umbellata by Use of Four Types of Glucanase," Carbohydrate Research, 65:235-243 (1978).
Reiskind, J. B. and Mullins, J. T., "Molecular Architecture of the Hyphal Wall of Achlya ambisexualis Raper. II. Ultrastructural Analyses and a Proposed Model.sup.1," J. Microbiol., 27:1100-1105 (1981).
Latge, J. P., et al., "Composition chimique et ultrastructure des parois des corps hyphaux et des azygospores de Conidiobolus obscurus,"J. Microbiol., 30:1507-1521 (1984).
Sherwood, E. R., et al., "Soluble Glucan and Lymphokine-activated Killer (LAK) Cells in the Therapy of Experimental Hepatic Metastases," Chemical Abstracts, 108:179752V (1988).
Hara, C., et al., "A Branched (1.fwdarw.3)-.beta.-D-Glucan From a Water Extract of Dictyophora indusiata FISCH," Carb. Res., 145:237-246 (1986).
Goldman, R., "Induction of a .beta.-1,3-D-Glucan Receptor in P388D1 Cells Treated with Retinoic Acid of 1,25-dihydroxyvitamin D.sub.3," Immunology, 63:319-324 (1988).
Konopski, Z., et al., "Phagocytosis of .beta.-1,3-D-Glucan-Derivatized Microbeads by Mouse Peritoneal Macrophages Involves Three Different Receptors," Scand. J. Immunol., 33:297-306 (1991).
Bacon, J. S. D., et al., "Glucan Components of the Cell Wall of Bakers' Yeast (Saccharomyces cerevisiae) Considered in Relation to its Ultrastructure," Chemical Abstracts, 71:109168c (1969).
Williams, D. L., et al., "Development of a Water-Soluble, Sulfated (1.fwdarw.3)-.beta.-D-Glucan Biological Response Modifier Derived from Saccharomyces cerevisiae," Carbohydrate Research, 235:247-257 (1992).
Williams, D. L., et al., "A Sequential Multi-Assay Protocol for the Preclinical Assessment of Natural Product Complex Carbohydrate Immunomodulators," Develop. Biol. Standard., 77:129-136 (1992).
Williams, D. L., et al., "Development, Physicochemical Characterization and Preclinical Efficacy Evaluation of a Water Soluble Glucan Sulfate Derived from Saccharomyces cerrevisiae," Immunopharmacology, 22:139-156 (1991).
Pretus, H. A., et al., "Isolation, Physicochemical Characterization and Preclinical Efficacy Evaluation of Soluble Scleroglucan.sup.1," The Journal of Pharmacology and Experimental Therapeutics, 500-510 (1991).
Jamas et al., "A Novel Class of Macrophage-Activating Immunomodulators", ACS Symposium Series, Polymeric Drugs and Delivery Systems, Chapter 5, pp. 44-51 (1991).
Stashenko et al., "Reduction of Infection-Stimulated Periapical Bone Resorption by the Biological Response Modifier PGG Glucan", J. Dent. Res. 74(1):323-330 (1995).
Stashenko et al., "Inhibition of Periapical Bone Resorption by a Biological Response Modifier", J. Dent. Res. 73 (IADR Abstracts) No. 146 (1994).
Babineau et al., "Randomized Phase I/II Trial of a Macrophage-Specific Immunomodulator (PGG-Glucan) in High-Risk Surgical Patients", Annals of Surgery 220(5):601-609 (1994).
Babineau et al., "A Phase II Multicenter, Double-Blind Ran
Easson, Jr. D. Davidson
Jamas Spiros
Ostroff Gary R.
Alpha-Beta Technology, Inc.
Robinson Douglas W.
White Everett
LandOfFree
Use of aqueous soluble glucan preparations to stimulate platelet does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of aqueous soluble glucan preparations to stimulate platelet, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of aqueous soluble glucan preparations to stimulate platelet will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1506455